Global Drug Eluting Balloons (DEB) Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 Now Available at ReportsandReports

Dallas, TX-- (SBWire) -- 05/04/2010 -- ReportsandReports Announce it Will Carry Global Drug Eluting Balloons (DEB) Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 Market Research Report in its Store.

Browse the complete Report on: http://www.reportsandreports.com/market-reports/global-drug-eluting-balloons-deb-pipeline-analysis-opportunity/

GlobalData’s report, “Global Drug Eluting Balloons (DEB) Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016” provides key data, information and analysis on the global drug eluting balloons (DEB) market, a key segment within the medical device industry. The report provides market landscape, competitive landscape and market trends information the drug eluting balloons (DEB) market. The report provides comprehensive information on the key trends affecting the market, and key analytical content on the market dynamics. The report also reviews the competitive landscape, key pipeline products and technology offerings. Drug Eluting Balloons (DEB) have recently come into the limelight following the Conformité Européenne (CE) approval of several DEB products and their consequent launch in Europe. The recently concluded clinical trials in Europe have produced superior results to the current interventions for a large number of indications such as in-stent restenosis, peripheral vascular disease and bifurcation lesions. The global drug eluting balloons (DEBs) market was valued at $60m in 2009 and is expected to be driven by increased adoption by physicians as long term clinical data is released, and as the device is adopted for newer indications such as peripheral vascular disease.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

Scope

• Key geographies covered include the US (United States), Canada, the UK (United Kingdom), Germany, France, Italy, Spain, Japan, China, India, Australia, and Brazil.

• Annualized market revenues data from 2002 to 2009, forecast forward for 7 years to 2016. Company shares data for 2009.

• Qualitative analysis of key market trends, market drivers, and restraints by each category within the drug eluting balloons (DEB) market.

• The report also covers information on the leading market players, the competitive landscape, and the leading pipeline products and technologies.

• Key players covered include Aachen Resonance, B. Braun, Bayer, Caliber Therapeutics, Cook Medical, Eurocor, Invatec and Lutonix.

Reasons to buy

• Develop business strategies by understanding the trends and developments that are driving the drug eluting balloons (DEB) market globally.

• Design and develop your product development, marketing and sales strategies.

• Exploit M&A opportunities by identifying market players with the most innovative pipeline.

• Develop market-entry and market expansion strategies.

• Identify key players best positioned to take advantage of the emerging market opportunities.

• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.

• What’s the next being thing in the drug eluting balloons (DEB) market landscape? – Identify, understand and capitalize.

• Make more informed business decisions from the insightful and in-depth analysis of the global drug eluting balloons (DEB) market and the factors shaping it.

1 Table of contents 2
• 1.1 List of Tables 4
• 1.2 List of Figures 4

2 Introduction and Overview 5
2.1 GlobalData Report Guidance 5

3 Major Cardiovascular Indications Approved for Drug Eluting Balloons (DEB): Disease Pathophysiology, Etiology, and Epidemiology 6
3.1 In-stent Restenosis 6
3.1.1 Introduction 6
3.1.2 Pathophysiology 6
3.1.3 Etiology: Risk Factors for the Disease 7
3.2 In-Stent Restenosis Epidemiology: Global 8
3.2.1 Treatment Flow Model 8
3.3 In-stent Restenosis: Device Based Treatment Modalities and their Outcomes 9
3.4 Peripheral Vascular Disease: Overview and Pathophysiology 10
3.4.1 Introduction 10
3.5 Peripheral Vascular Disease Epidemiology: Global 11
3.5.1 Treatment Flow Model 11
3.6 Peripheral Vascular Disease: Device Based Treatment Modalities and their Outcomes 12

4 Global Drug Eluting Balloons Market : Market Characterization 14
4.1 Global Drug Eluting Balloons Market, Revenue ($m), 2007–2016 14
4.2 Global Drug Eluting Balloons Market, Volume (Units), 2007–2016 15
4.3 Drug Eluting Balloons, Market Dynamics 15
4.3.1 Market Drivers 15
4.3.2 Market Restraints 17
4.4 Drug Eluting Balloons: Unmet Need and Opportunities 17
4.4.1 Unmet Need 18
4.4.2 Opportunities 18

5 Global Drug Eluting Balloons (DEB) Market: Cross-Country Market Analysis and Forecasts 19
5.1 Global Drug Eluting Balloons Market: Cross-Country Analysis 19
5.2 Drug Eluting Balloons (DEB), Revenue, By Country, 2007 – 2016 20
5.2.1 Drug Eluting Balloons Market, Germany, Revenue ($m), 2007 – 2016 20
5.2.2 Drug Eluting Balloons Market, France, Revenue ($m), 2007 – 2016 21
5.2.3 Drug Eluting Balloons Market, UK, Revenue ($m), 2007 – 2016 22
5.2.4 Drug Eluting Balloons Market, Italy, Revenue ($m), 2007 – 2016 23
5.2.5 Drug Eluting Balloons Market, Spain, Revenue ($m), 2007 – 2016 24
5.2.6 Drug Eluting Balloons Market, Australia, Revenue ($m), 2009 – 2016 25
5.2.7 Drug Eluting Balloons Market, India, Revenue ($m), 2009 – 2016 26
5.2.8 China Drug Eluting Balloons Market, Revenue ($m), 2009 – 2016 27

6 Global Drug Eluting Balloons Market: Company Share Analysis and Key Market Participants 28
6.1 Global Drug Eluting Balloons Market, Company Share (%), 2009 28
6.2 B Braun 28
6.2.1 Overview 28
6.2.2 Drug Eluting Balloons Portfolio 29
6.3 Eurocor 29
6.3.1 Overview 29
6.4 Invatec 30
6.4.1 Overview 30
6.4.2 Drug Eluting Balloons Portfolio 30
6.5 Aachen Resonance GmbH 31
6.5.1 Overview 31
6.5.2 Drug Eluting Balloons Portfolio 31

7 Global Drug Eluting Balloons Market: Key Marketed Products 32
7.1 SeQuent Please 32
7.1.1 Product Overview and Description 32
7.1.2 Key Technology 32
7.1.3 Clinical Study Results 32
7.2 DIOR Paclitaxel-Eluting Coronary Balloon Catheter 34
7.2.1 Product Overview and Description 34
7.2.2 Key Technology 35
7.2.3 Clinical Study Results 35
7.3 Elutax 35
7.3.1 Product Overview and Description 35
7.3.2 Key Technology 35
7.3.3 Clinical Study Results 36
7.4 IN.PACT Amphirion Paclitaxel Eluting Balloon Catheter 36
7.4.1 Product Description 36
7.4.2 Key Technology 36
7.4.3 Clinical Study Results 37

8 Global Drug Eluting Balloons Market: Strategic Pipeline Assessment 38
8.1 Pipeline Technology Assessment 38
8.1.1 Pipeline Technology Assessment for Drug Eluting Balloons by Development Stage 38
8.1.2 Pipeline Technology Assessment for Drug Eluting Balloons by Unmet Need 39
8.1.3 Novel Pipeline Technology Assessment for Drug Eluting Balloons 40
8.2 Drug Eluting Balloons: List of Pipeline Products 41
8.3 Profiles of Promising Products under Clinical Development 42
8.3.1 Lutonix 42
8.3.2 Advance 18PTX 47
8.3.3 Cotavance 48
8.3.4 Genesis DESA Catheter 48
8.3.5 Drug-Eluting PTA Balloon Catheter 48
8.3.6 Drug-Eluting Balloon 49
8.3.7 PTCA Balloon Genistein-coated balloon catheter 49

9 Global Drug Eluting Balloons Market: Strategic Deals Analysis 50
9.1 Key Acquisitions 50
9.1.1 Medtronic Acquired Invatec 50
9.1.2 MEDRAD Completes Acquisition Of Possis Medical 50
9.1.3 Opto Circuits Acquired Eurocor 50
9.2 Key Partnerships 50
9.2.1 Maxcor entered a strategic agreement with Micell Technologies to develop new balloon and stent system 50
9.2.2 Eurocor enters distribution agreement with Goodman for entering Japan market in 2007 51
9.2.3 MEDRAD Enters Into Licensing Agreement With B. Braun Melsungen 51
9.2.4 DSM Biomedical and Caliber Therapeutics form partnership to develop a drug-delivery balloon catheter to treat atherosclerosis. 51
9.2.5 Aachen Resonance enters into a distribution agreement with Biotronik to distribute Elutax in Europe 52

10 Appendix 53
10.1 Definitions 53
10.1.1 Interventional Cardiology 53
10.1.2 Peripheral Vascular Devices 53
10.1.3 Drug Eluting Balloons 54
10.2 Acronyms 54
10.3 Research Methodology 54
10.4 Secondary Research 55
10.5 Primary Research 55
10.6 Models 55
10.7 Forecasts 56
10.8 Expert Panels 56
10.9 GlobalData Consulting 56
10.10 Contact Us 56
10.11 Disclaimer 56

1.1 List of Tables
• Table 1: Drug Eluting Balloons Market, Global, Revenue($m), 2007–2016 14
• Table 2: Drug Eluting Balloons Market, Global, Volume (Units), 2007 – 2016 15
• Table 3: Drug Eluting Balloons Market, Global, Revenue and Growth Comparison 19
• Table 4: Drug Eluting Balloons Market, Germany, Revenue ($m), 2007 – 2016 20
• Table 5: Drug Eluting Balloons Market, France, Revenue ($m), 2007 – 2016 21
• Table 6: Drug Eluting Balloons Market, UK, Revenue ($m), 2007 – 2016 22
• Table 7: Drug Eluting Balloons Market, Italy, Revenue ($m), 2007 – 2016 23
• Table 8: Drug Eluting Balloons Market, Spain, Revenue ($m), 2007 – 2016 24
• Table 9: Drug Eluting Balloons Market, Australia, Revenue ($m), 2009 – 2016 25
• Table 10: Drug Eluting Balloons Market, India, Revenue ($m), 2009 – 2016 26
• Table 11: Drug Eluting Balloons Market, China, Revenue ($m), 2009 – 2016 27
• Table 12: Drug Eluting Balloons Market, Global, Key Company Shares (%), 2009 28
• Table 13: B Braun, Drug Eluting Balloons, Pipeline Products 29
• Table 14: Eurocor, Drug Eluting Balloons, Pipeline Products 30
• Table 15: Invatec, Drug Eluting Balloons, Pipeline Products 31
• Table 16: Aachen Resonance, Drug Eluting Balloons, Pipeline Products 31
• Table 17: List of Pipeline Products, Drug Eluting Balloons 41
• Table 18: Lutonix Balloon angioplasty catheter - A Prospective, Multicenter, European Registry Investigating The Lutonix Paclitaxel-Coated Balloon For The Treatment Of In-Stent Restenosis Within Bare-Metal Stents 42
• Table 19: Lutonix Balloon angioplasty catheter - An Exploratory Study Investigating the Use of the Lutonix Paclitaxel-Coated Balloon in Conjunction With Bare Metal Stenting in Patients With De Novo Coronary Lesions. 44
• Table 20: Lutonix Balloon angioplasty catheter - A Prospective, Multicenter, Single Blind, Randomized, Controlled Trial Comparing the Lutonix Catheter vs. Standard Balloon Angioplasty for Treatment of Femoropopliteal Arteries With and Without Stenting. 45
• Table 21: Advance 18 PTX Balloon Catheter - Advance 18PTX Balloon Catheter Study: Treatment of Lesions in Superficial Femoral Artery/Popliteal Artery With a Paclitaxel-coated Balloon 47

1.2 List of Figures
• Figure 1: Treatment Flow Model, Drug Eluting Balloons for Treatment of In-stent restenosis, 2009 8
• Figure 2: Device Based Treatment Modalities for In-Stent Restenosis 9
• Figure 3: Treatment Flow Model, Drug Eluting Balloons for Treatment of Peripheral Artery Disease, 2009 11
• Figure 4: Device Based Treatment Modalities for Peripheral Vascular Disease 12
• Figure 5: Drug Eluting Balloons Market, Global, Revenue ($m), 2007–2016 14
• Figure 6: Drug Eluting Balloons Market, Global, Volume (Units), 2007 – 2016 15
• Figure 7: Unmet Need and Opportunities Analysis for Drug Eluting Balloons 17
• Figure 8: Drug Eluting Balloons Market, Global, Revenue and Growth Comparison 19
• Figure 9: Drug Eluting Balloons Market, Germany, Revenue ($m), 2007 – 2016 20
• Figure 10: Drug Eluting Balloons Market, France, Revenue ($m) , 2007 – 2016 21
• Figure 11: Drug Eluting Balloons Market, UK, Revenue ($m), 2007 – 2016 22
• Figure 12: Drug Eluting Balloons Market, Italy, Revenue ($m), 2007 – 2016 23
• Figure 13: Drug Eluting Balloons Market, Spain, Revenue ($m), 2007 – 2016 24
• Figure 14: Drug Eluting Balloons Market, Australia, Revenue ($m), 2009 – 2016 25
• Figure 15: Drug Eluting Balloons Market, India, Revenue ($m), 2009 – 2016 26
• Figure 16: Drug Eluting Balloons Market, China, Revenue ($m), 2009 – 2016 27
• Figure 17: Drug Eluting Balloons Market, Global, Company Share (%), 2009 28
• Figure 18: Pipeline Technology Assessment for Drug Eluting Balloons By Development Stage, Europe 38
• Figure 19: Pipeline Technology Assessment for Drug Eluting Balloons By Development Stage, US 39
• Figure 20: Pipeline Technology Assessment for Drug Eluting Balloons by Unmet Need 39
• Figure 21: Novel Pipeline Technology Assessment for Drug Eluting Balloons 40
• Figure 22: GlobalData Methodology 54

Related Reports:
Global Drug Eluting Stent Market 2008-2012
http://www.reportsandreports.com/market-reports/global-drug-eluting-stent-market-2008-2012/

Drug Eluting Stents (DES) Pipeline Technology and Market Forecasts to 2016
http://www.reportsandreports.com/market-reports/drug-eluting-stents-des-pipeline-technology-and-market-forecast/

European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries)
http://www.reportsandreports.com/market-reports/european-markets-for-drug-eluting-and-bare-metal-stents-2009-15-/

About ReportsandReports
ReportsandReports comprises an online library of 10,000 reports, in-depth market research studies of over 5000 micro markets, and 25 industry specific websites. Our client list boasts almost all well-known publishers of such reports across the globe. We as a third-party reseller of market research reports employ a number of marketing tools, such as press releases, email-marketing and effective search-engine optimization techniques to drive revenues for our clients. We also provide 24/7 online and offline support service to our customers.

Contact:
Ms. Sunita
7557 Rambler road,
Suite 727, Dallas, TX 75231
Tel: +1-888-989-8004
http://www.reportsandreports.com/
http://reportsnreports.wordpress.com/